Literature DB >> 6652606

Utilization of psychotropic drugs in Saskatchewan: 1977-1980.

B Power, W Downey, B R Schnell.   

Abstract

Psychotropic drug use in Saskatchewan during 1977, 1978, 1979 and 1980 was determined. Approximately one in five prescriptions dispensed was for a psychotropic. About 20% of the population received psychotropic drugs in each year but use has declined slightly, especially that of tranquilizers. Psychotropic use increased with the patient's age and nearly two-thirds were women. Considerable caution should be exercised in making comparisons with other drug utilization studies. There may be substantial differences in the drugs selected for study, the categorization of these drugs, and the methodology used to analyze drug use. Also, most studies are based on data that is from a decade old or older. Moreover, most if not all other studies on drug use are based on sample surveys (from different sampling universes), whereas the present study is based on the entire population. Nevertheless, some generalizations may be valid. Since non-formulary drugs are excluded, the findings should be regarded as conservative. Examples of non-formulary drugs considered to be psychotropic include antispasmodic/tranquilizer/sedative combinations (example: Librax, Donnatal), combination hypnotics (example: Tuinal, Mandrax), and some combination analgesics (example: propoxyphene compounds, pentazocine compound, oxycodone compound).

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6652606     DOI: 10.1177/070674378302800708

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  2 in total

1.  Benzodiazepine use and abuse in Canada.

Authors:  U Busto; K L Lanctôt; P Isaac; M Adrian
Journal:  CMAJ       Date:  1989-11-01       Impact factor: 8.262

2.  A population-wide profile of prescription drug use in Saskatchewan, 1989.

Authors:  K Quinn; M J Baker; B Evans
Journal:  CMAJ       Date:  1992-06-15       Impact factor: 8.262

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.